DRUGS & SUPPLEMENTS
How long you have been taking the medicine?
When used orally, Manoketo has been associated with hepatic toxicity, including some fatalities. Patients receiving this drug should be informed by the physician of the risk and should be closely monitored. See WARNINGS and PRECAUTIONS sections.
Coadministration of terfenadine with Manoketo tablets is contraindicated. Rare cases of serious cardiovascular adverse events, including death, ventricular tachycardia and torsades de pointes have been observed in patients taking Manoketo tablets concomitantly with terfenadine, due to increased terfenadine concentrations induced by Manoketo tablets. See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections.
Pharmacokinetic data indicate that oral Manoketo inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals. Coadministration of astemizole with Manoketo tablets is therefore contraindicated. See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections.
Coadministration of cisapride with Manoketo is contraindicated. Serious cardiovascular adverse events including ventricular tachycardia, ventricular fibrillation and torsades de pointes have occurred in patients taking Manoketo concomitantly with cisapride. See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections.
Manoketo is a synthetic broad-spectrum antifungal agent. Each tablet, for oral administration, contains 200 mg Manoketo base. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Manoketo is (±)cis-1-Acetyl-4-[p-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine and has the following structural formula:
C26H28Cl2N4O4 M.W. 531.44
Manoketo is a white to slightly beige, odorless powder that is soluble in acids.
Mean peak plasma levels of approximately 3.5 mcg/mL are reached within 1 to 2 hours, following oral administration of a single 200 mg dose taken with a meal. Subsequent plasma elimination is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter. Following absorption from the gastrointestinal tract, Manoketo is converted into several inactive metabolites. The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, oxidative O-dealkylation and aromatic hydroxylation. About 13% of the dose is excreted in the urine, of which 2 to 4% is unchanged drug. The major route of excretion is through the bile into the intestinal tract. In vitro, the plasma protein binding is about 99% mainly to the albumin fraction. Only a negligible proportion of Manoketo reaches the cerebral-spinal fluid. Manoketo is a weak dibasic agent and thus requires acidity for dissolution and absorption.
Manoketo tablets are active against clinical infections with Blastomyces dermatitidis, Candida spp., Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis, and Phialophora spp. Manoketo tablets are also active against Trichophyton spp., Epidermophyton spp., and Microsporum spp. Manoketo is also active in vitro against a variety of fungi and yeast. In animal models, activity has been demonstrated against Candida spp., Blastomyces dermatitidis, Histoplasma capsulatum, Malassezia furfur, Coccidioides immitis, and Cryptococcus neoformans.
In vitro studies suggest that Manoketo impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes.
Manoketo tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Manoketo tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid.
Manoketo tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin.
Coadministration of terfenadine or astemizole with Manoketo tablets is contraindicated. (See BOX WARNING, WARNINGS, and PRECAUTIONS sections.)
Concomitant administration of Manoketo tablets with cisapride is contraindicated. (See BOX WARNINGS, WARNINGS and PRECAUTIONS sections.)
Concomitant administration of Manoketo tablets with oral triazolam is contraindicated. (See PRECAUTIONS section.)
Manoketo is contraindicated in patients who have shown hypersensitivity to the drug.
Hepatotoxicity, primarily of the hepatocellular type, has been associated with the use of Manoketo tablets, including rare fatalities. The reported incidence of hepatotoxicity has been about 1:10,000 exposed patients, but this probably represents some degree of under-reporting, as is the case for most reported adverse reactions to drugs. The median duration of Manoketo tablet therapy in patients who developed symptomatic hepatotoxicity was about 28 days, although the range extended to as low as 3 days. The hepatic injury has usually, but not always, been reversible upon discontinuation of Manoketo tablet treatment. Several cases of hepatitis have been reported in children.
Prompt recognition of liver injury is essential. Liver function tests (such as SGGT, alkaline phosphatase, SGPT, SGOT and bilirubin) should be measured before starting treatment and at frequent intervals during treatment. Patients receiving Manoketo tablets concurrently with other potentially hepatotoxic drugs should be carefully monitored, particularly those patients requiring prolonged therapy or those who have had a history of liver disease.
Most of the reported cases of hepatic toxicity have to date been in patients treated for onychomycosis. Of 180 patients worldwide developing idiosyncratic liver dysfunction during Manoketo tablet therapy, 61.3% had onychomycosis and 16.8% had chronic recalcitrant dermatophytoses.
Transient minor elevations in liver enzymes have occurred during treatment with Manoketo tablets. The drug should be discontinued if these persist, if the abnormalities worsen, or if the abnormalities become accompanied by symptoms of possible liver injury.
In rare cases anaphylaxis has been reported after the first dose. Several cases of hypersensitivity reactions including urticaria have also been reported.
Coadministration of Manoketo tablets and terfenadine has led to elevated plasma concentrations of terfenadine which may prolong QT intervals, sometimes resulting in life- threatening cardiac dysrhythmias. Cases of torsades de pointes and other serious ventricular dysrhythmias, in rare cases leading to fatality, have been reported among patients taking terfenadine concurrently with Manoketo tablets. Coadministration of Manoketo tablets and terfenadine is contraindicated.
Coadministration of astemizole with Manoketo tablets is contraindicated. (See BOX WARNING, CONTRAINDICATIONS, and PRECAUTIONS sections.)
Concomitant administration of Manoketo tablets with cisapride is contraindicated because it has resulted in markedly elevated cisapride plasma concentrations and prolonged QT interval, and has rarely been associated with ventricular arrhythmias and torsades de pointes. (See BOXED WARNING, CONTRAINDICATIONS and PRECAUTIONS sections.)
In European clinical trials involving 350 patients with metastatic prostatic cancer, eleven deaths were reported within two weeks of starting treatment with high doses of Manoketo tablets (1200 mg/day). It is not possible to ascertain from the information available whether death was related to Manoketo therapy in these patients with serious underlying disease. However, high doses of Manoketo tablets are known to suppress adrenal corticosteroid secretion.
In female rats treated three to six months with Manoketo at dose levels of 80 mg/kg and higher, increased fragility of long bones, in some cases leading to fracture, was seen. The maximum "no-effect" dose level in these studies was 20 mg/kg (2.5 times the maximum recommended human dose). The mechanism responsible for this phenomenon is obscure. Limited studies in dogs failed to demonstrate such an effect on the metacarpals and ribs.
Manoketo tablets have been demonstrated to lower serum testosterone. Once therapy with Manoketo has been discontinued, serum testosterone levels return to baseline values. Testosterone levels are impaired with doses of 800 mg per day and abolished by 1600 mg per day. Manoketo tablets also decrease ACTH induced corticosteroid serum levels at similar high doses. The recommended dose of 200 mg to 400 mg daily should be followed closely.
In four subjects with drug-induced achlorhydria, a marked reduction in Manoketo absorption was observed. Manoketo tablets require acidity for dissolution. If concomitant antacids, anticholinergics, and H2-blockers are needed, they should be given at least two hours after administration of Manoketo tablets. In cases of achlorhydria, the patients should be instructed to dissolve each tablet in 4 mL aqueous solution of 0.2 N HCl. For ingesting the resulting mixture, they should use a drinking straw so as to avoid contact with the teeth. This administration should be followed with a cup of tap water.
Patients should be instructed to report any signs and symptoms which may suggest liver dysfunction so that appropriate biochemical testing can be done. Such signs and symptoms may include unusual fatigue, anorexia, nausea and/or vomiting, jaundice, dark urine or pale stools.
Manoketo is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of Manoketo tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. The following drug interactions have been identified involving Manoketo tablets and other drugs metabolized by the cytochrome P450 enzyme system.
Manoketo tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite. The increased plasma concentration of terfenadine or its metabolite may result in prolonged QT intervals. (See BOX WARNING, CONTRAINDICATIONS, and WARNINGS sections.)
Pharmacokinetic data indicate that oral Manoketo inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals. Coadministration of astemizole with Manoketo tablets is therefore contraindicated. (See BOX WARNING, CONTRAINDICATIONS, and WARNINGS sections.)
Human pharmacokinetics data indicate that oral Manoketo potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride. Data suggest that coadministration of oral Manoketo and cisapride can result in prolongation of the QT interval on the ECG. Therefore concomitant administration of Manoketo tablets with cisapride is contraindicated. (See BOX WARNING, CONTRAINDICATIONS and WARNINGS sections.)
Manoketo tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs. Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with Manoketo tablets.
Coadministration of Manoketo tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. These agents should not be used in patients treated with Manoketo tablets. If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.
Rare cases of elevated plasma concentrations of digoxin have been reported. It is not clear whether this was due to the combination of therapy. It is, therefore, advisable to monitor digoxin concentrations in patients receiving Manoketo.
When taken orally, imidazole compounds like Manoketo may enhance the anticoagulant effect of coumarin-like drugs. In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with Manoketo tablets (an imidazole) can not be ruled out.
Concomitant administration of Manoketo tablets with phenytoin may alter the metabolism of one or both of the drugs. It is suggested to monitor both Manoketo and phenytoin.
Concomitant administration of rifampin with Manoketo tablets reduces the blood levels of the latter. INH (Isoniazid) is also reported to affect Manoketo concentrations adversely. These drugs should not be given concomitantly.
After the coadministration of 200 mg oral Manoketo twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (± 142 S.D.) and 251% (± 68 S.D.), respectively, of those obtained after co-treatment with placebo. The AUC and Cmax of descarboethoxyloratadine, an active metabolite, averaged 155% (± 27 S.D.) and 141% (± 35 S.D.), respectively. However, no related changes were noted in the QTc on ECG taken at 2, 6, and 24 hours after the coadministration. Also, there were no clinically significant differences in adverse events when loratadine was administered with or without Manoketo.
Rare cases of disulfiram-like reaction to alcohol have been reported. These experiences have been characterized by flushing, rash, peripheral edema, nausea, and headache. Symptoms resolved within a few hours.
The dominant lethal mutation test in male and female mice revealed that single oral doses of Manoketo as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames Salmonella microsomal activator assay was also negative. A long term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity.
Manoketo has been shown to be teratogenic in the rat when given in the diet at 80 mg/kg/day (10 times the maximum recommended human dose). However, these effects may be related to maternal toxicity, evidence of which also was seen at this and higher dose levels.
There are no adequate and well controlled studies in pregnant women. Manoketo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Manoketo has also been found to be embryotoxic in the rat when given in the diet at doses higher than 80 mg/kg during the first trimester of gestation. In addition, dystocia (difficult labor) was noted in rats administered oral Manoketo during the third trimester of gestation. This occurred when Manoketo was administered at doses higher than 10 mg/kg (higher than 1.25 times the maximum human dose).
It is likely that both the malformations and the embryotoxicity resulting from the administration of oral Manoketo during gestation are a reflection of the particular sensitivity of the female rat to this drug. For example, the oral LD50 of Manoketo given by gavage to the female rat is 166 mg/kg whereas in the male rat the oral LD50 is 287 mg/kg.
Since Manoketo is probably excreted in the milk, mothers who are under treatment should not breast feed.
Manoketo tablets have not been systematically studied in children of any age, and essentially no information is available on children under 2 years. Manoketo should not be used in pediatric patients unless the potential benefit outweighs the risks.
In rare cases, anaphylaxis has been reported after the first dose. Several cases of hypersensitivity reactions including urticaria have also been reported. However, the most frequent adverse reactions were nausea and/or vomiting in approximately 3%, abdominal pain in 1.2%, pruritus in 1.5%, and the following in less than 1% of the patients: headache, dizziness, somnolence, fever and chills, photophobia, diarrhea, gynecomastia, impotence, thrombocytopenia, leukopenia, hemolytic anemia, and bulging fontanelles. Oligospermia has been reported in investigational studies with the drug at dosages above those currently approved. Oligospermia has not been reported at dosages up to 400 mg daily, however sperm counts have been obtained infrequently in patients treated with these dosages. Most of these reactions were mild and transient and rarely required discontinuation of Manoketo tablets. In contrast, the rare occurrences of hepatic dysfunction require special attention (see WARNINGS section).
In worldwide postmarketing experience with Manoketo tablets there have been rare reports of alopecia, paresthesia, and signs of increased intracranial pressure including bulging fontanelles and papilledema. Hypertriglyceridemia has also been reported but a causal association with Manoketo is uncertain.
Neuropsychiatric disturbances, including suicidal tendencies and severe depression, have occurred rarely in patients using Manoketo tablets.
Ventricular dysrhythmias (prolonged QT intervals) have occurred with the concomitant use of terfenadine with Manoketo tablets. (See BOX WARNING, CONTRAINDICATIONS, and WARNINGS sections.)
Data suggest that coadministration of Manoketo tablets and cisapride can result in prolongation of the QT interval and has rarely been associated with ventricular arrhythmias. (See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections.)
In the event of accidental overdosage, supportive measures, including gastric lavage with sodium bicarbonate, should be employed.
Adults: The recommended starting dose of Manoketo tablets is a single daily administration of 200 mg (one tablet). In very serious infections or if clinical responsiveness is insufficient within the expected time, the dose of Manoketo may be increased to 400 mg (two tablets) once daily.
Children: In small numbers of children over 2 years of age, a single daily dose of 3.3 to 6.6 mg/kg has been used. Manoketo tablets have not been studied in children under 2 years of age.
There should be laboratory as well as clinical documentation of infection prior to starting Manoketo therapy. Treatment should be continued until tests indicate that active fungal infection has subsided. Inadequate periods of treatment may yield poor response and lead to early recurrence of clinical symptoms. Minimum treatment for candidiasis is one or two weeks. Patients with chronic mucocutaneous candidiasis usually require maintenance therapy. Minimum treatment for the other indicated systemic mycoses is six months.
Minimum treatment for recalcitrant dermatophyte infections is four weeks in cases involving glabrous skin. Palmar and plantar infections may respond more slowly. Apparent cures may subsequently recur after discontinuation of therapy in some cases.
Each Manoketo tablet, USP contains Manoketo 200 mg available in bottles of 100 and 500. The tablets are white, round, flat-beveled tablets, debossed “93”-“900” on the scored side, plain on the other side.
Store at controlled room temperature between 20° and 25° C (68° and 77° F).
Protect from moisture.
TEVA PHARMACEUTICALS USA
Sellersville, PA 18960
Printed in USA
Rev. C 11/2003
Manoketo structural formula
Depending on the reaction of the Manoketo after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Manoketo not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Manoketo addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology